Date: Monday, June 4, 2018
Session Name: Poster Session C: Liver: Immunosuppression and Rejection
Session Time: 6:00pm-7:00pm
Presentation Time: 6:00pm-7:00pm
Location: Hall 4EF
Background: Deceased donor orthotopic liver transplantation (OLT) can result in significant delayed function, manifesting as protracted hyperbilirubinemia, depending on the intensity of the ischemia/reperfusion injury (IRI). We recently changed our OLT protocol to include corticosteroid (CS) tapering post-transplant, as an anti-inflammatory agent against IRI.
Methods: We performed a retrospective cohort study of 208 OLTs performed at our center since 2002. We compared one-week post-OLT bilirubin levels between those that did and did not receive CS.
Results: The CS group consisted of 67 patients vs. 141 non-CS patients. Demographics were similar between the groups (table 1). Dosing of calcineurin inhibitors and antimetabolites was similar between the groups. One week median tacrolimus levels were slightly higher in the non-CS group vs. the CS group (7.0 ng/mL IQR (4.8-9.7) vs. 5.1 ng/mL IQR (3.0-7.8)). Median cold ischemia time (CIT) was shorter in the non-CS group vs. CS group (10 hours IQR (8.3-11.1) vs. 9.1 hours IQR (7.0-10.0), p = 0.02). Despite the shorter CIT, total bilirubin at 7 days post-OLT was increased in the non-CS group vs. the CS group (4.73 mg/dL IQR (2.1-11.2) vs. 2.21 mg/dL IQR (1.2-7.6), p = 0.001). Calculated MELD scores utilizing labs at one week were lower in the CS vs. non-CS group, likely related to the total bilirubin (non-CS = 15.2 vs. CS = 12.6, p = 0.02).
Conclusion: Our results suggest that the advantages of CS may extend beyond prevention of rejection. These findings should be confirmed in randomized studies to account for potential unmeasured confounders.
|CS (n=67)||Non-CS (n=141)|
|Deceased Donors Age > 60||27%||24%|
|Donation after Cardiac Death Donors||0%||4%|
|Donor BMI, median (IQR)||25.7 (22.4-29.9)||26.0 (23.2-30.3)|
|Recipient Age, median (IQR)||55 (51-63)||57 (50-60)|
|Recipient ethnicity, African American||21%||16%|
|Liver disease secondary to HCV||42%||61%|
|Tacrolimus based Immunosuppression||97%||98%|
CITATION INFORMATION: Malat G., Reich D., Xiao G., Harhay M., Ranganna K., Lee D., Guy S., Munoz S. Adjunctive Corticosteroid Immunosuppression Improves Hyperbilirubinemia Following Liver Transplantation (OLT) Am J Transplant. 2017;17 (suppl 3).
To cite this abstract in AMA style:Malat G, Reich D, Xiao G, Harhay M, Ranganna K, Lee D, Guy S, Munoz S. Adjunctive Corticosteroid Immunosuppression Improves Hyperbilirubinemia Following Liver Transplantation (OLT) [abstract]. https://atcmeetingabstracts.com/abstract/adjunctive-corticosteroid-immunosuppression-improves-hyperbilirubinemia-following-liver-transplantation-olt/. Accessed January 25, 2021.
« Back to 2018 American Transplant Congress